Echosens

21/07/2025

Too often, primary care and other providers must go through specialists like hepatologists for liver screenings. Endocrinologist Grajower, MD says it best—this barrier is as illogical as requiring a breast surgeon to order a mammogram.

📊 The U.S. has only around 9,500 hepatologists—and many patients don’t see them until their liver disease is already irreversible.

With MASLD and MASH now recognized as major cardiovascular risk factors, providers on the front lines of care who are managing metabolic health need access to noninvasive, cost-effective, and efficient tools like FibroScan®.

18/07/2025

Last week, Echosens supported a busy liver health screening event for staff at North Tees Hospital by providing an additional FibroScan® device to help meet high demand.
This was the second event of its kind, following an overwhelming response to the first session earlier this year. A third event is already planned for the Hartlepool site in August.

More than 250 employees total have taken part, completing a liver health questionnaire from the British Liver Trust before receiving a quick, non-invasive test with . A team of liver specialists were on hand throughout the day, offering a walk-in service and valuable liver health advice.

We’re also pleased to share that Tees Valley Community Diagnostic Centre will soon benefit from FibroScan® technology through a new liver pathway pilot—helping to expand access to early detection and monitoring of liver disease in the community.

🙏Thanks to Super Scanners, Donna, Tracy, Sam and Andrea, liver nurses covering North Tees & Hartlepool Hospitals.

17/07/2025

This week we would like to welcome, Richmond Primary Care, to our ! If patients in primary care with metabolic disease also have MASLD, they double their risk of cardiovascular disease. FibroScan® can help identify these patients early!
🫱🏻‍🫲🏻Thank you, Richmond Primary Care, for joining us in the fight against MASLD in primary care.
📣Is your practice part of the ? We’d love to hear about your program!

15/07/2025

🎉 Echosens is proud to announce that FibroScan® is now available in 11 United Digestive clinics across Georgia and Florida.

This partnership enhances United Digestive’s ability to detect liver disease earlier and develop tailored care plans based on patient risk factors.

John Suh, MD, MPH, gastroenterologist and chief medical officer at United Digestive, says, “We see the impact of obesity and metabolic dysfunctions every day in our clinics. FibroScan allows us to identify at-risk patients earlier and determine the most appropriate care pathways, whether that’s nutrition counseling, lifestyle modifications, referrals to hepatologists, or additional tests and treatments.”

Marc Sonenshine, MD, gastroenterologist and EVP for clinical initiatives at United Digestive, adds, “The demand has been significant, and it’s clear how valuable this tool has become in our clinics.”

We’re excited to continue building this partnership to empower more patients to take charge of their liver health.

See press release for full details: https://www.prnewswire.com/news-releases/echosens-and-united-digestive-partner-to-expand-access-to-non-invasive-liver-diagnostics-302504566.html?tc=eml_cleartime

11/07/2025

Echosens and our customers are all after the same goal: to make liver health management accessible to all.
Cary Endocrine and Diabetes Center is leading the way by offering FibroScan® for their patients at risk for liver disease in the endocrinology setting.
🩺Thank you for partnering with Echosens, so that together we can work toward shaping the future of liver health.
🔦Help us spotlight more practices making a difference — Tag them below for a chance to be featured!

09/07/2025

🎬 Did that just happen?! FibroScan® by Echosens made an appearance on Good Morning America. ⭐📺

In a segment spotlighting the silent epidemic of MASLD/MASH, commonly called fatty liver disease, Naim Alkhouri —hepatologist and world-renowned thought leader—used FibroScan to help show how non-invasive tools (NITs) are changing the game in early detection.

💡 38% of adults are affected by MASLD worldwide, and most don’t even know it. But that’s starting to change, thanks to national media attention and healthcare providers adopting point-of-care NITs like FibroScan that make early detection possible.

🎥 Watch the clip. Spot the FibroScan. And join the movement to make liver care routine. https://www.goodmorningamerica.com/video/123006818

ABC News' Dr. Tara Narula breaks down the condition affecting nearly one in four Americans and the promising treatment giving patients new hope.

04/07/2025

📰 New Paper: ® in stratifying fibrosis in 📰

In individuals with suspected metabolic dysfunction and alcohol-associated liver disease (MetALD), LSM by VCTE™ > 8kPa showed high diagnostic accuracy in detecting significant fibrosis—with a an AUROC of 0.85, sensitivity of 80%, specificity of 91%, 99% NPV. ​
When combined with the Fibrosis-4 (FIB-4) index in a stepwise approach, it minimizes false negatives to 2%, ensuring accurate detection and timely intervention.

​➡️ Only 11% of participants needed specialist referral, highlighting the efficiency and cost-effectiveness of this noninvasive pathway in primary care— one that aligns with clinical guidelines and promotes better patient outcomes.

30/06/2025

⚠️ Metabolic dysfunction-associated steatotic liver disease (MASLD), commonly called “fatty liver disease,” is more than a liver condition—it’s a warning sign that is often overlooked in patients with obesity, prediabetes, and type 2 diabetes (T2D).

Unlike hepatitis, MASLD is metabolic in nature. It frequently coexists with obesity, T2D, and cardiovascular disease, yet is rarely part of the conversation.

Here’s why it should be:
➡️ 38% of adults are affected by MASLD worldwide
➡️ 65% or more of individuals with T2D have MASLD
➡️ Doubles the risk of heart attack or stroke
➡️ Triples the risk of developing diabetes

Fat accumulation in the liver isn’t just a downstream effect of metabolic dysfunction—it’s an active driver of it. Recognizing MASLD as part of metabolic dysfunction should transform cardiometabolic care and patient outcomes.

27/06/2025

📺 Únase a nosotros en próximo webinar con Novo Nordisk el 3 de Julio - Abordaje holístico de la EHmet: Un camino de ida y vuelta.

🩺 Un encuentro donde expertos en el abordaje de esta patología compartirán su visión sobre el papel de cada disciplina en la prevención, diagnóstico precoz, manejo y seguimiento de esta patología.
Forma parte de este diálogo clave sobre el abordaje integral de los pacientes.

📅 Una conferencia ineludible para los profesionales de la salud: https://event.on24.com/wcc/r/4984987/0483F50CF3F63ADBADDE2CB0DEB19B72?partnerref=ES

24/06/2025

🚨 Discover myBaveno, a tool to assist in the management of portal hypertension! 🚨
Developed and approved by healthcare professionals, myBaveno offers you an interactive access to recommendations about portal hypertension management from VII publication.
👉 Get started today with this clinical decision support software, intended to provide healthcare professionals with relevant context on liver stiffness measured by ® devices.
It is now available in English and French ➡️ https://www.echosens.com/mybaveno/

19/06/2025

We're excited to announce that Echosens is attending the 85th American Diabetes Association, starting tomorrow through June 23, in Chicago, IL.
Come meet us at booth N°3725! The whole team looks forward to showing you the Next Generation FibroScan® at the booth!


American Diabetes Association – DiabetesPro

17/06/2025

🔥Últimos días para inscribirse en el sobre el uso de la elastografía esplénica en la práctica clínica para el manejo de la hipertensión portal, impartido por el Prof. José Luis Calleja (Madrid) y Jose Presa Ramos (Vila Real).

🩺Programa
🔹Importancia del estudio de la rigidez esplénica
🔹Identificación de problemas y estratificación del riesgo
🔹Foco en marcadores no invasivos: LSM by VCTE™, SSM by VCTE™, plaquetas
🔹Recomendaciones internacionales (Baveno VII)
🔹Diferencia marca el poder tener un equipo que la estudie
🔹Casos clínicos reales
🔹Sesión de preguntas y respuestas en directo

📅 No te pierdas la sesión del 18 de junio
https://event.on24.com/wcc/r/4966373/CF22A43686AE187A08956F6C1FD61718?partnerref=Facebook